新西兰批准在青年使用率上升和公共卫生问题持续存在的情况下,首次采用以蒸发为基础的尼古丁替代疗法。 New Zealand approves first vaping-based nicotine replacement therapy amid rising youth use and ongoing public health concerns.

新西兰批准了其首例排气专用尼古丁替代疗法(NRT),允许从排气中治疗尼古丁依赖性,阿斯马和呼吸系统基金会欢迎这一举动。 New Zealand has approved its first vaping-specific nicotine replacement therapy (NRT), allowing treatment for nicotine dependence from vaping, a move welcomed by the Asthma and Respiratory Foundation. 该批准承认电子烟已成为日益严重的公共卫生问题，尤其是在青少年中，使用率正在上升。 The approval recognizes vaping as a growing public health concern, especially among youth, with rising usage rates. 虽然新疗法支持那些想戒烟的人,但基金会强调预防至关重要,并敦促制定更严格的条例,包括禁止在一般商店销售输卵管和阻止新的专科输卵管零售商。 While the new therapy supports those seeking to quit, the Foundation stresses prevention is critical and urges stricter regulations, including banning vape sales in general stores and halting new specialist vape retailers. 尽管要求政府为以学校为基础的教育方案提供资金,但该团体得不到支持,并继续依靠捐款。 Despite requesting government funding for school-based education programs, the group was denied support and continues relying on donations. 特别是在毛利人社区,在实现2025年无烟化目标方面取得的进展仍然令人关切。 Concerns remain about progress toward the Smokefree 2025 goal, particularly for Māori communities.